Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Abstract Bromocriptine-QR (quick release) is a novel treatment for type 2 diabetes. The objective of this study is to assess the efficacy and safety of bromocriptine-QR in adults with type 2 diabetes mellitus based on randomized controlled trials published in peer-reviewed journals or as abstracts. We performed a comprehensive literature search of MEDLINE, Pubmed, Web of Science, EMBASE, and the Cochrane Library up to May 2015. Randomized controlled trials of bromocriptine-QR therapy in type 2 diabetes mellitus were eligible. Two reviewers independently assessed the eligibility of trials based on predefined inclusion criteria. Information was collected concerning basic study data, patient characteristics, efficacy and safety outcomes, and methodological quality. Bromocriptine-QR add-on therapy lowered hemoglobin A1c compared with placebo (weighted mean difference, − 6.52 mmol/mol; 95% CI, − 8.07 to − 4.97 mmol/mol). Bromocriptine-QR exhibited an increase in achieving an HbA1c level≤53 mmol/mol (≤ 7.0%) (32.0 vs. 9.5%; odds ratio, 4.57; 95% CI, 2.42–8.62). Fasting plasma glucose was reduced with bromocriptine-QR compared with placebo (weighted mean difference,−1.04 mmol/l; 95% CI,−1.49 to−0.59 mmol/l). Moreover, bromocriptine-QR had neutral effects on postprandial glycemia, Body Mass Index (BMI), and lipid profile. Bromocriptine-QR had more gastrointestinal side effects of nausea and vomiting. Bromocriptine-QR had no increased risk of hypoglycemia, hypotension, or cardiovascular effects. Bromocriptine-QR therapy offers an alternative option to currently available antidiabetic agents for type 2 diabetes mellitus adults. Neither hypoglycemia nor other metabolic changes occur with this drug. More data for long-term efficacy and safety are needed for further observation.

[1]  L. Wilkins.  Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects , 2015, Journal of the American Heart Association.

[2]  P. Raskin,et al.  Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study , 2015, Journal of diabetes research.

[3]  A. Cincotta,et al.  Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats , 2014, Diabetology & Metabolic Syndrome.

[4]  N. Sengupta,et al.  Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial , 2014, Indian journal of pharmacology.

[5]  W. Drake,et al.  A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. , 2014, The Journal of clinical endocrinology and metabolism.

[6]  A. Cincotta,et al.  Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. , 2012, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[7]  D. Bell.  Focusing on Cardiovascular Disease in Type 2 Diabetes Mellitus: An Introduction to Bromocriptine QR , 2012, Postgraduate medicine.

[8]  P. García-Pavía,et al.  No clinically significant valvular regurgitation in long‐term cabergoline treatment for prolactinoma , 2012, Clinical endocrinology.

[9]  S. Zacharieva,et al.  Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. , 2012, European journal of endocrinology.

[10]  Z. Bloomgarden,et al.  Hypoglycemia in Type 2 Diabetes: Current Controversies and Changing Practices , 2012, Front. Endocrin..

[11]  H. Anthony.  Weighted Effects of Bromocriptine Treatment on Glucose Homeostasisduring Hyperglycemic versus Euglycemic Clamp Conditions in Insulin Resistant Hamsters: Bromocriptine as a Unique Postprandial Insulin Sensitizer , 2012 .

[12]  C. Boguszewski,et al.  A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas , 2012, Pituitary.

[13]  A. Cincotta,et al.  Randomized Clinical Trial Assessing the Efficacy and Safety of Bromocriptine-QR when Added to Ongoing Thiazolidinedione Therapy in Patients with Type 2 Diabetes Mellitus , 2011 .

[14]  D. Bell.  Why does quick‐release bromocriptine decrease cardiac events? , 2011, Diabetes, obesity & metabolism.

[15]  M. Ezzati,et al.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants , 2011, The Lancet.

[16]  Jaiprakash Ramanand,et al.  Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes , 2011, Indian journal of endocrinology and metabolism.

[17]  R. DeFronzo.  Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes , 2011, Diabetes Care.

[18]  S. Kalra,et al.  Dopamine: the forgotten felon in type 2 diabetes. , 2011, Recent patents on endocrine, metabolic & immune drug discovery.

[19]  M. Rubinstein,et al.  Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. , 2010, Endocrinology.

[20]  Michael A. Via,et al.  Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes , 2010, Diabetes, metabolic syndrome and obesity : targets and therapy.

[21]  C. O'connor,et al.  Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes , 2010, Diabetes Care.

[22]  A. Cincotta,et al.  Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes , 2010, Expert opinion on pharmacotherapy.

[23]  G. Reynolds,et al.  Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. , 2010, Pharmacology & therapeutics.

[24]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[25]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[26]  Y. Chan,et al.  Bromocriptine use and the risk of valvular heart disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[27]  F. Andersohn,et al.  Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists , 2009, Movement disorders : official journal of the Movement Disorder Society.

[28]  A. Cincotta,et al.  Quick release bromocriptine (Cycloset™) a novel treatment for type 2 diabetes also demonstrates improvements in blood pressure , 2009 .

[29]  W. Poewe,et al.  Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease , 2007, The Lancet Neurology.

[30]  E. Chung,et al.  Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists , 2006, Movement disorders : official journal of the Movement Disorder Society.

[31]  S. Carobbio,et al.  Dopamine D2-like Receptors Are Expressed in Pancreatic Beta Cells and Mediate Inhibition of Insulin Secretion* , 2005, Journal of Biological Chemistry.

[32]  Werner Poewe,et al.  Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 , 2005, Movement disorders : official journal of the Movement Disorder Society.

[33]  Charles M Peterson,et al.  Tests of glycemia in diabetes. , 1995, Diabetes care.

[34]  N. Yanagisawa,et al.  Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[35]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[36]  J. Lancaster,et al.  Bromocriptine: a novel approach to the treatment of type 2 diabetes. , 2000, Diabetes care.

[37]  A. Cincotta,et al.  Chronic Ventromedial Hypothalamic Infusion of Norepinephrine and Serotonin Promotes Insulin Resistance and Glucose Intolerance , 1999, Neuroendocrinology.

[38]  A. Cincotta,et al.  Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. , 1999, Expert opinion on investigational drugs.

[39]  A. Cincotta,et al.  Bromocriptine Reduces Obesity, Glucose Intolerance and Extracellular Monoamine Metabolite Levels in the Ventromedial Hypothalamus of Syrian Hamsters , 1998, Neuroendocrinology.

[40]  D. Brooks,et al.  Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study , 1998, Movement disorders : official journal of the Movement Disorder Society.

[41]  A. Cincotta,et al.  Effects of a Quick-Release Form of Bromocriptine (Ergoset) on Fasting and Postprandial Plasma Glucose, Insulin, Lipid, and Lipoprotein Concentrations in Obese Nondiabetic Hyperinsulinemic Women , 1997, Diabetes Care.

[42]  O. Rascol,et al.  Prevalence of orthostatic hypotension in Parkinson’s disease , 1997, Journal of neurology, neurosurgery, and psychiatry.

[43]  A. Cincotta,et al.  Circadian rhythms regulate the- expression of the thrifty genotypelphenotype , 1996 .

[44]  M. Lam,et al.  Domperidone for Drug-Induced Orthostatic Hypotension-A Review , 1992 .

[45]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[46]  A. Tadepalli,et al.  Cardiovascular actions of bromocriptine: evidence for a neurogenic mechanism. , 1979, The Journal of pharmacology and experimental therapeutics.

[47]  S. Kaye,et al.  Letter: Bromocriptine and hypertension. , 1976, Lancet.